)
Immuneering (IMRX) investor relations material
Immuneering Study update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Atebimetinib rationale and pipeline
Oral, once-daily third-generation MEK inhibitor designed for deep, transient pathway inhibition followed by a recovery window; intended to improve tolerability and preserve body mass.
Combination programs span chemotherapy, CLDN18.2-targeted agents, PRMT5 inhibitors, G12D/G12V inhibitors and immunotherapy.
Atebimetinib plus cemiplimab study expected to dose its first patient by year-end; an NSCLC anti-PD-1 program is also planned to start before year-end.
Pancreatic cancer
Interim Phase 2 analysis of 55 patients treated at 320 mg once daily showed median overall survival of 17.3 months; 84% of evaluable patients maintained or gained weight at 3 months. H1 2027 update planned.
MAPKeeper 301, a global Phase 3 trial of atebimetinib plus gemcitabine/nab-paclitaxel in first-line metastatic disease, began dosing and was enrolling ahead of schedule; topline results expected mid-2028.
Two Astellas-sponsored studies will test investigational CLDN18.2 combinations: one adds a CLDN18.2 candidate to atebimetinib plus mGnP in first-line disease; the other tests a chemotherapy-free regimen in previously treated disease.
Astellas will sponsor and conduct the studies, and atebimetinib supply will be provided; each party retains development and commercialization rights to its respective investigational medicines. The collaboration is the fourth pharma partnership.
Anaplastic thyroid cancer
Planned Phase 2 study evaluates second-line atebimetinib plus carboplatin and pemetrexed in MAPK-altered ATC after first-line standard treatment; cohorts address BRAF V600E and other eligible disease.
Design includes a six-patient safety run-in, followed by cohorts of ~29 patients each; atebimetinib dose is 320 mg. Primary endpoint is objective response rate.
Secondary endpoints include duration of response, disease control rate, progression-free survival, safety and overall survival; study was designed with investigators from four leading ATC centers and is considered potentially registrational.
IND submission planned by year-end; pending regulatory clearance, first dosing targeted for mid-2027, with top-line results potentially 12–18 months after dosing begins.
MAP kinase pathway drivers occur in most ATC cases, including ~40% with BRAF mutations and 33% with other mutations; second-line options remain limited.
- MAPKeeper-301 enrollment is ahead of schedule, with top-line data guided for mid-2028.IMRX
3rd Annual Guggenheim Healthcare Innovation Conference - Atebimetinib + mGnP showed 86% 9-month OS; a randomized Phase 3 trial is planned.IMRX
Study update - Higher trial spending lifted losses as runway guidance moved to Q4 2028.IMRX
Q3 2026 - Atebimetinib delivers 17.3 months median OS in first-line pancreatic cancer with high tolerability.IMRX
H.C. Wainwright 28th Annual Global Investment Conference - Atebimetinib nearly doubles survival in first-line pancreatic cancer with superior tolerability.IMRX
12th Annual Cantor Fitzgerald Global Healthcare Conference - Pivotal trial for atebimetinib advanced, with strong interim data and cash runway into 2029.IMRX
Q2 2026 - Atebimetinib shows strong survival and tolerability in pancreatic cancer, with pivotal phase III underway.IMRX
25th Annual Needham Virtual Healthcare Conference - Atebimetinib plus mGnP achieved 94% 6-month OS and strong tolerability in pancreatic cancer.IMRX
Study Update - IMM-1-104 achieved 43% ORR and 86% DCR with strong tolerability in first-line pancreatic cancer.IMRX
Study Result
)
)
)
)
)
)
)
)